Geulah Livshits
Stock Analyst at Chardan Capital
(0.29)
# 2161
Out of 5,218 analysts
179
Total ratings
31.13%
Success rate
7.02%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Editas Medicine | Downgrades: Neutral | n/a | n/a | n/a | 10 | Dec 13, 2024 | |
Krystal Biotech | Maintains: Buy | 212 212 | 163.31 | 29.81% | 7 | Dec 12, 2024 | |
CRISPR Therapeutics | Maintains: Buy | 94 94 | 43.75 | 114.86% | 11 | Dec 10, 2024 | |
Senti Biosciences | Maintains: Strong Buy | 10 12 | 5.57 | 115.44% | 7 | Dec 4, 2024 | |
Immuneering | Maintains: Buy | 13 13 | 1.64 | 692.68% | 8 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 15 15 | 3.31 | 353.17% | 5 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 62 62 | 12.02 | 415.81% | 14 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 88 91 | 12.89 | 605.97% | 12 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 7 7 | 0.74 | 845.95% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 7 7 | 2.06 | 239.81% | 11 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 39 39 | 6.49 | 500.92% | 6 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 17 15 | 2.9 | 417.24% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 23 25 | 6.92 | 261.27% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 28 28 | 13.72 | 104.08% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 15 15 | 4.93 | 204.26% | 4 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 17 11 | 1.22 | 801.64% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 20 18 | 2.75 | 554.55% | 8 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 11 6 | 0.99 | 506.06% | 5 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 29 34 | 7.83 | 334.23% | 10 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 41 41 | 6.12 | 569.93% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 28 25 | 7.22 | 246.26% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 12 | 2.8 | 328.57% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 30 25 | n/a | n/a | 4 | Mar 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 191 208 | 41.83 | 397.25% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 160 40 | n/a | n/a | 3 | Dec 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 15 16 | 1.83 | 774.32% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 4 3 | 7.5 | -66.67% | 5 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 450 270 | n/a | n/a | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 100 90 | 8.27 | 988.27% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 6 4 | 6.25 | -36% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 20 | n/a | n/a | 1 | Oct 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 33 30 | 0.19 | 15689.47% | 2 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 50 30 | 5.38 | 457.62% | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 18 | 12.59 | 42.97% | 1 | Oct 27, 2020 |